https://www.selleckchem.com/pr....oducts/liproxstatin-
Though desensitization remains to be the first choice for DHS for many dental practitioners and most of desensitizing agents reduce the symptoms of DHS by occluding patent dentinal tubules, the long-term outcome of such treatment is uncertain. With improved understanding of the underlying nociceptive mechanisms of DHS, it is expected that promising novel therapies will emerge and provide more effective relief for patients with DHS. Differentiation of mouse trophoblast stem cells (TSCs) to trophoblast giant cells (TGCs) has been w
Like
Comment
Share
